Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)

You may also be interested in...



Roche’s Pirfenidone Bet Validates China Venture

China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.

Cenova Touts Experience In Assessing Risk Of China Drug Development With Aslan Financing

Taking on the risk of a biotech investment in China takes experience, according to Shanghai-based Cenova Ventures, as a recent Series B finance round with Aslan Pharmaceuticals shows.

Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report

China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.

Related Content

UsernamePublicRestriction

Register

SC073207

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel